Karuna Therapeutics Inc (OQ:KRTX)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 33 Arch St Ste 3110
BOSTON MA 02110-1424
Tel: N/A
Website: https://karunatx.com
IR: See website
<
Key People
Steven M. Paul
Chairman of the Board, Chief Executive Officer
Andrew Craig Miller
Founder, Chief Operating Officer
Troy A. Ignelzi
Chief Financial Officer
Giorgio Attardo
Vice President, CMC and Preclinical Development
Stephen K Brannan
Chief Medical Officer
 
Business Overview
Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to address disabling neuropsychiatric conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is developing a pipeline of therapeutic programs to address symptoms associated with schizophrenia and psychosis associated with Alzheimer's disease (AD), as well as various forms of pain. KarXT is a combination of xanomeline and trospium.
Financial Overview
For the nine months ended 30 September 2019, Karuna Therapeutics Inc revenues was not reported. Net loss increased from $9.2M to $36.2M. Higher net loss reflects Research and development increase from $4.7M to $19.2M (expense), Stock-based Compensation in SGA increase from $446K to $11.2M (expense), General and administrative - Balancing v increase from $671K to $3.3M (expense).
Employees: 17 as of Jun 30, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $2,557M as of Sep 30, 2019
Annual revenue (TTM): $0.00M as of Sep 30, 2019
EBITDA (TTM): -$44.64M as of Sep 30, 2019
Net annual income (TTM): -$44.51M as of Sep 30, 2019
Free cash flow (TTM): -$31.17M as of Sep 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 26,012,754 as of Nov 20, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization